| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| LIU FANG-YU | Chairman | 17.41% | Liu Handa Holdings,LLC |
| Chang, Mei Fang | Director | 17.41% | Liu Handa Holdings,LLC |
| Chen,Jun-Liang | Director | 17.41% | Liu Handa Holdings,LLC |
| Lin,Wei-Li | Director | 17.41% | Liu Handa Holdings,LLC |
| Lu,Li-An | Director | 10.74% | ScinoPharm Taiwan,Ltd. |
| Ma,Hai-Yi | Director | 0.01% | |
| Wu, Jinn | Independent Director | 0.00% | |
| Xu,Da-Cheng | Independent Director | 0.00% | |
| Zhou,Pei-Fen | Independent Director | 0.00% |
Change Company Name to Handa Pharmaceuticals, Inc.
2024/07/03
Change Capital to 1,800,000,000
2023/06/26
Change Company Name to HANDA BIOTECH PHARMACEUTICAL CO., LTD. (FORMER NAME: HUARUI BIOTECH PHARMACEUTICAL CO., LTD.)
2022/08/30
Change Capital to 1,500,000,000
2019/07/12
Change Person in Charge to LIUFANG-YU
2019/07/12
Change Company Name to Handa Pharmaceuticals, Inc.
2016/05/11
Change Person in Charge to LIUFANG-YU
2016/04/18
Change Capital to 1,300,000,000
2016/04/01
Change Person in Charge to Chen,Jun-Liang
2014/10/03
下載完整報告查看完整數據
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating income | 432,905 | 1,106,320 | 197,676 |
| Operating cost | 599 | 1,301 | 18,711 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 432,306 | 1,105,019 | 178,965 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 432,306 | 1,105,019 | 178,965 |
| Operating expenses | 199,957 | 411,592 | 267,085 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | 232,349 | 693,427 | -88,120 |
| Non-operating income and expenses | 44,006 | 99,060 | 44,970 |
| Net profit (loss) before tax | 276,355 | 792,487 | -43,150 |
| Income tax expense (benefits) | 56,892 | 65,601 | -3,139 |
| Net profit (loss) of ongoing business for the current period | 219,463 | 726,886 | -40,011 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | 219,463 | 726,886 | -40,011 |
| Other comprehensive profit (loss), net | 50,018 | -12,945 | -22,912 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | 269,481 | 713,941 | -62,923 |
| Net profit (loss) attributable to owners of parent company | 219,463 | 726,886 | -40,011 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | 269,481 | 713,941 | -62,923 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | 1 | 5 | 0 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | 317,068 | 668,360 | -211,571 |
| Net cash inflows (outflows) from investing activities | -31,996 | -1,664,500 | 29,503 |
| Net cash inflow (outflow) from financing activities | -140,866 | 1,305,616 | 313,645 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 24,068 | -8,342 | -28,974 |
| Increase (decrease) in cash and cash equivalents in the current period | 168,274 | 301,134 | 102,603 |
| Beginning balance of cash and cash equivalents | 667,046 | 365,912 | 263,309 |
| Ending balance of cash and cash equivalents | 835,320 | 667,046 | 365,912 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current asset | 2,768,082 | 2,714,874 | 592,857 |
| Non-current asset | 377,858 | 322,316 | 197,707 |
| Total asset | 3,145,940 | 3,037,190 | 790,564 |
| Current liability | 155,989 | 209,486 | 45,354 |
| Non-current liability | 88,715 | 71,395 | 24,088 |
| Total liability | 244,704 | 280,881 | 69,442 |
| share capital | 1,413,840 | 1,410,940 | 1,301,630 |
| Equity - secruity token | - | - | - |
| capital reserve | 1,252,416 | 1,253,347 | 579,017 |
| retained earning | 293,577 | 215,202 | -1,088,684 |
| Other equity | -58,597 | -123,180 | -70,841 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 2,901,236 | 2,756,309 | 721,122 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 2,901,236 | 2,756,309 | 721,122 |
| Share capital awaiting retirement (unit: share) | - | - | - |
| Issued shares of advance equity (unit: shares) | 100,000 | 0 | 3,000 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 20 | 19 | 5 |
